相似文献
1
Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections.
NPJ Vaccines. 2020 Nov 3;5(1):103. doi: 10.1038/s41541-020-00256-6.
2
Access to safe blood in low-income and middle-income countries: lessons from India.
BMJ Glob Health. 2017 May 18;2(2):e000167. doi: 10.1136/bmjgh-2016-000167. eCollection 2017.
3
Transfusion-transmitted infections: existing and emerging pathogens.
J Postgrad Med. 2005 Apr-Jun;51(2):146-51.
4
[Transfusion-transmitted protozoal infections: what is the risk in non-endemic countries?].
Acta Med Port. 2011 Dec;24 Suppl 4:897-906. Epub 2011 Dec 31.
5
Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses.
J Clin Virol. 2005 Dec;34 Suppl 2:S75-80. doi: 10.1016/s1386-6532(05)80038-1.
6
European strategies against the parasite transfusion risk.
Transfus Clin Biol. 2005 Feb;12(1):1-4. doi: 10.1016/j.tracli.2004.12.001.
7
The risk of transfusion-transmitted infections in sub-Saharan Africa.
Transfusion. 2010 Feb;50(2):433-42. doi: 10.1111/j.1537-2995.2009.002402.x. Epub 2009 Oct 15.
8
Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
Transfus Apher Sci. 2015 Feb;52(1):19-34. doi: 10.1016/j.transci.2014.12.016. Epub 2014 Dec 30.
9
Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
Lancet. 2020 Jul 11;396(10244):97-109. doi: 10.1016/S0140-6736(20)30543-2. Epub 2020 May 20.
10
Reproductive-tract infections in women in low-income, low-prevalence situations: assessment of syndromic management in Matlab, Bangladesh.
Lancet. 1999 Nov 20;354(9192):1776-81. doi: 10.1016/s0140-6736(99)02463-0.
引用本文的文献
1
Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19.
Front Med (Lausanne). 2021 Sep 6;8:743325. doi: 10.3389/fmed.2021.743325. eCollection 2021.
2
Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
Transfus Clin Biol. 2021 Aug;28(3):225-227. doi: 10.1016/j.tracli.2021.07.005.
3
International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary.
Vox Sang. 2021 Nov;116(10):1117-1135. doi: 10.1111/vox.13113. Epub 2021 May 20.
本文引用的文献
1
Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.
NPJ Vaccines. 2020 Jul 6;5:58. doi: 10.1038/s41541-020-0209-2. eCollection 2020.
2
Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries.
Vox Sang. 2021 Jan;116(1):18-35. doi: 10.1111/vox.12970. Epub 2020 Jul 20.
3
Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.
Vox Sang. 2021 Jan;116(1):13-14. doi: 10.1111/vox.12964. Epub 2020 Jun 24.
4
Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.
Vox Sang. 2020 Aug;115(6):485-487. doi: 10.1111/vox.12939. Epub 2020 May 14.
5
Ebola: a call for blood transfusion strategy in sub-Saharan Africa.
Lancet. 2014 Oct 11;384(9951):1347-8. doi: 10.1016/S0140-6736(14)61693-7. Epub 2014 Sep 29.
Zotero 插件